FRACTYL HEALTH, INC. (GUTS) Latest Company News

Oct 16, 2026, 11:00 UTC
FRACTYL HEALTH, INC. reported that its ongoing REMAIN-1 pivotal study met the six-month co-primary endpoint, with 80% retention of GLP-1-induced weight loss for Revita versus 67% for sham.
Source:
- globenewswire.com
Sep 23, 2026, 21:31 UTC
Kuehn Law, PLLC is investigating whether certain officers and directors of Fractyl Health, Inc. breached their fiduciary duties to shareholders.
Source:
- prnewswire.com
Sep 15, 2026, 14:48 UTC
SueWallSt reminded shareholders of an October 20, 2026 lead plaintiff deadline in the securities class action lawsuit against Fractyl Health, Inc. (GUTS), in which CEO Harith Rajagopalan and former CFO Lisa A. Davidson face Section 20(a) control person claims over allegedly overstated Revita DMR efficacy data.
Source:
- globenewswire.com
Sep 3, 2026, 14:40 UTC
A class action lawsuit was filed against Fractyl Health, Inc. on behalf of investors who purchased securities between January 13, 2025 and January 29, 2026.
Source:
Sep 1, 2026, 16:00 UTC
Glancy Prongay Wolke & Rotter LLP announced a securities fraud lawsuit on behalf of Fractyl Health, Inc. shareholders who suffered losses, related to the company's disclosure of REMAIN-1 Midpoint Cohort data on January 29, 2026.
Source:
- wallstreet-online.de
Aug 14, 2026, 09:04 UTC
Fractyl Health launched a clinical trial for its Rejuva gene therapy, a one-time treatment for obesity and type 2 diabetes.
Source:
- marketbeat.com
Aug 10, 2026, 23:05 UTC
Fractyl Health announced that its Revita endoscopic procedure demonstrated durable weight-maintenance results one year after patients discontinued GLP-1 therapy.
Source:
- marketbeat.com
Jul 15, 2026, 13:03 UTC
Fractyl Health reported one-year data from the REMAIN-1 study showing its Revita procedure helped patients maintain weight loss after stopping GLP-1 therapy.
Source:
- marketbeat.com
- zacks.com

GUTS

FRACTYL HEALTH, INC. reported that its ongoing REMAIN-1 pivotal study met the six-month co-primary endpoint, with 80% retention of GLP-1-induced weight loss for Revita versus 67% for sham.

Kuehn Law, PLLC is investigating whether certain officers and directors of Fractyl Health, Inc. breached their fiduciary duties to shareholders.

A class action lawsuit was filed against Fractyl Health, Inc. on behalf of investors who purchased securities between January 13, 2025 and January 29, 2026.

Glancy Prongay Wolke & Rotter LLP announced a securities fraud lawsuit on behalf of Fractyl Health, Inc. shareholders who suffered losses, related to the company's disclosure of REMAIN-1 Midpoint Cohort data on January 29, 2026.

Fractyl Health launched a clinical trial for its Rejuva gene therapy, a one-time treatment for obesity and type 2 diabetes.

Fractyl Health announced that its Revita endoscopic procedure demonstrated durable weight-maintenance results one year after patients discontinued GLP-1 therapy.

Fractyl Health reported one-year data from the REMAIN-1 study showing its Revita procedure helped patients maintain weight loss after stopping GLP-1 therapy.